Web Exclusives

The American Cancer Society reports good news regarding the overall lower rate of cancer-related mortalities in the United States, but also points to some disturbing trends.
The FDA approval of avapritinib marks the first time a drug has been approved specifically for patients with GIST harboring PDGFRA exon 18 mutations, which are involved in approximately 10% of GIST cases.
The FDA has confirmed another strong year regarding the approval of innovative new drugs and biosimilars, including several agents used in the treatment of patients with cancer.
Pancreatic cancer is a difficult to treat malignancy with a high mortality rate. Patients are usually diagnosed with advanced disease, and many are not eligible for surgery. Although systemic therapy is a mainstay of treatment, there are limited options for patients with metastatic disease. We invite you to read more about some of the recent observational data on metastatic pancreatic cancer treatment patterns, patient outcomes, and costs in an effort to shed insights into real-world clinical decisions and the economic factors that influence them.
  • Brukinsa Receives Accelerated FDA Approval for Mantle-Cell Lymphoma
  • Ziextenzo Third Biosimilar to Neulasta Approved for Febrile Neutropenia
  • Tecentriq Approved with Chemotherapy for First-Line Treatment of Metastatic NSCLC without EGFR or ALK Mutations
  • FDA Approves Calquence for Adults with CLL or SL
  • Zejula Receives FDA Approval for HRD-Positive Advanced Ovarian Cancer
On December 12, 2019, the FDA issued draft guidance to implement amendments to the Federal Food, Drug, and Cosmetic (FD&C) Act that will facilitate early assessment of studies of molecularly targeted oncology drugs that may be effective in the treatment of pediatric cancers.
The ovarian cancer patients’ internal dialogue may delay a cancer diagnosis and can also overestimate the capability of chemotherapy.
BRCA wild-type tumors are more common in women with ovarian cancer and may need higher doses of the tumor-targeting PARP inhibitor.
The rise in the number of cancer drugs taken orally has placed a renewed focus on the importance—and challenges—of patient adherence to self-administered oral medications.
While Medicare Part D enrollees may see their out-of-pocket expenses, deductibles, and premiums increase in 2020, protections of the drugs used in cancer treatment will remain in place.
Page 1 of 24
Results 1 - 10 of 236